chartexchange

Telo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells

Newsfile | Nov 18, 2026 6:30 AM EST

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today announced that it has signed a term sheet dated as of August 20, 2026, providing an option to obtain an exclusive worldwide commercial license with the University of Manitoba and Technion...

Read original article